We are live on ! Find out more
CLVS

Clovis Oncology, Inc.
CLVS

Delisted

CLVS was delisted on the 20th of December, 2022.

Back to rankings

192 hedge funds and large institutions have $3.27B invested in Clovis Oncology, Inc. in 2015 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 88 increasing their positions, 45 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 45

71% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 24

18% more capital invested

Capital invested by funds: $2.76B → $3.27B (+$507M)

9% more funds holding

Funds holding: 176 → 192 (+16)

0% more funds holding in top 10

Funds holding in top 10: 13 → 13 (0)

4% less call options, than puts

Call options by funds: $49.6M | Put options by funds: $51.5M

Holders
192
Holders Change
+16
Holders Change %
+9.09%
% of All Funds
5.36%
Holding in Top 10
13
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.36%
New
41
Increased
88
Reduced
45
Closed
24
Calls
$49.6M
Puts
$51.5M
Net Calls
-$1.96M
Net Calls Change
+$955K

Top Buyers

1
AA
Antipodean Advisors
New York
+$113M
2
Viking Global Investors
Viking Global Investors
Connecticut
+$72.4M
3
PAI
Palo Alto Investors
California
+$61.2M
4
Wells Fargo
Wells Fargo
California
+$52.5M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$36.1M

Top Sellers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$50.3M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$25M
3
CCM
Consonance Capital Management
New York
-$22.3M
4
SAM
Sectoral Asset Management
Quebec, Canada
-$21.7M
5
PC
PointState Capital
New York
-$17.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
GCP
201
GSA Capital Partners
United Kingdom
– -$1.23M -14,000 Closed
RCM
202
RA Capital Management
Massachusetts
– -$1.16M -13,200 Closed
LCG
203
Lisanti Capital Growth
New York
– -$628K -7,150 Closed
SIM
204
Spark Investment Management
New York
– -$615K -7,000 Closed
HTC
205
Hershey Trust Company
Pennsylvania
– -$557K -6,335 Closed
PSC
206
Piper Sandler & Co
Minnesota
– -$308K -3,500 Closed
BCM
207
Bourgeon Capital Management
Connecticut
– -$277K -3,150 Closed
FAB
208
First American Bank
Illinois
– -$252K -2,870 Closed
FANJ
209
Financial Architects (New Jersey)
New Jersey
– -$176K -2,000 Closed
GT
210
Glenmede Trust
Pennsylvania
– -$49K -565 Closed
TRCT
211
Tower Research Capital (TRC)
New York
– -$32K -368 Closed
JG
212
Jefferies Group
New York
– -$19.5K -225 Closed
PAM
213
Panagora Asset Management
Massachusetts
– -$10K -112 Closed
W
214
Wealthfront
California
– +$433 +5 New
HNB
215
Huntington National Bank
Ohio
– +$779 +9 New
5 6 7 8
9

CLVS Hedge Fund Activity: Q3 2015 in Review

192 of the 3,581 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2015, worth a combined $3.27B — up 18% from $2.76B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new CLVS positions and 24 closed out — a net gain of 17 holders — while 88 added to existing stakes and 45 trimmed.

The largest buyer was Antipodean Advisors, opening a new position worth an estimated $113M. The largest seller was Lord, Abbett & Co, cutting an estimated $50.3M.

  • 192 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2015, up from 176 in Q2 2015.
  • Funds reported $3.27B of Clovis Oncology, Inc. stock for Q3 2015, up 18% quarter-over-quarter.
  • 41 funds opened new Clovis Oncology, Inc. positions in Q3 2015 and 24 closed out, a net change of +17 holders.
  • The largest Clovis Oncology, Inc. buyer in Q3 2015 was Antipodean Advisors, an estimated $113M added.
  • The largest Clovis Oncology, Inc. seller in Q3 2015 was Lord, Abbett & Co, an estimated $50.3M sold.

Based on aggregated 13F filings for Q3 2015.